CGM Use Linked to Lower Mortality Risk in Older Adults With Type 1 Diabetes

Researchers at the Veterans Health Administration examined health records from over 8,400 adults with Type 1 diabetes to compare mortality outcomes between those who started using continuous glucose monitors (CGM) and those who did not. Over a follow-up period of 1 to 4 years, the CGM group had measurably lower death rates. The adjusted mortality risk was between 10% and 16% lower in CGM users across different follow-up timeframes.

The benefit persisted even when researchers adjusted their analysis for different definitions of the study period, suggesting the findings were robust and not dependent on a specific analytical choice.

The mortality reduction with CGM was strongest in two groups: adults older than 65 and people not using insulin pumps. This suggests that certain populations may experience greater health advantage from continuous glucose monitoring, though the study did not fully explain why.

Interestingly, the mortality benefit did not differ based on blood sugar control (measured by HbA1c), race, ethnicity, or frailty level—suggesting that the protective effect was fairly consistent across different types of patients.

This study used observational data rather than a randomized controlled trial. This means researchers compared groups of people who chose (or were prescribed) CGM with those who were not, rather than randomly assigning people to use or not use the device. Because of this design, the study shows an association between CGM use and lower mortality, not definitive proof that CGM causes the reduction.

The researchers took several steps to address this limitation, including matching groups carefully and adjusting for known differences between CGM users and non-users. They also checked whether the mortality benefit might be explained by unrelated health conditions—finding that it was not—which adds credibility to their findings.

The study included only veterans, so results may not apply equally to all populations with Type 1 diabetes.

This research adds to growing evidence that CGM systems do more than improve day-to-day glucose management. The findings suggest that over years of use, CGM may be associated with meaningful health outcomes like reduced mortality risk, particularly in older adults.

While this is promising, the study does not prove that CGM directly causes longer survival. More research, ideally randomized trials, would be needed to confirm whether the association reflects a true protective benefit of the technology. Anyone considering CGM should discuss its potential benefits and fit with their healthcare provider, not based on this single study, but as part of a broader conversation about their diabetes management and health goals.

Source: Diabetes care. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.